Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer

NCT07811076 | Not Yet Recruiting Phase 1

• 1 other identifier: Approval No. 1280 (2026)
• Study Type: interventional
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase Ib/II seamless, open-label, randomized controlled trial evaluating the safety and efficacy of a serine/glycine-restricted diet combined with neoadjuvant chemoradiotherapy and immunotherapy in patients with locally advanced rectal cancer (LARC). The study consists of two phases. Phase Ib is a non-randomized, single-arm safety run-in phase enrolling 6 patients, all of whom will receive the experimental regimen (serine/glycine-restricted diet plus CAPOX chemotherapy, PD-1 inhibitor, and short-course radiotherapy). The primary objective of Phase Ib is to assess safety, tolerability, and dietary compliance. If the safety criteria are met (≥3 grade diet-related adverse event rate ≤20% and compliance rate ≥70%), the study will proceed to Phase II. Phase II is a randomized, open-label, parallel-controlled phase in which 134 additional patients will be randomized in a 1:1 ratio to either the experimental group (serine/glycine-restricted diet plus standard neoadjuvant chemoradiotherapy and immunotherapy) or the control group (standard neoadjuvant chemoradiotherapy and immunotherapy alone). The total enrollment is 140 patients (6 in Phase Ib + 134 in Phase II). The primary endpoint is the complete response rate (pCR + cCR). Secondary endpoints include major pathological response (MPR) rate, R0 resection rate, mrTRG regression grade, event-free survival (EFS), progression-free survival (PFS), overall survival (OS), adverse event profile, changes in serum amino acid levels, quality of life (EORTC QLQ-C30), and nutritional status. Exploratory endpoints include gut microbiome diversity and tumor immune microenvironment changes.

Conditions

Locally Advanced Rectal Cancer (LARC)

Outcome Measures

Primary Outcomes (1)

• Complete Response Rate (pCR + cCR)

  At the time of surgery, approximately 6-8 weeks after completion of all 6 cycles of neoadjuvant chemoradiotherapy and immunotherapy

Secondary Outcomes (10)

• Major Pathological Response (MPR) Rate

  At the time of radical surgery, approximately 24 weeks after initiation of neoadjuvant treatment.

• R0 Resection Rate

  At the time of radical surgery, approximately 24 weeks after initiation of neoadjuvant treatment.

• mrTRG Regression Grade

  Up to approximately 24 weeks after initiation of neoadjuvant treatment (at the time of pre-surgery imaging assessment).

• Event-Free Survival (EFS)

  Up to 5 years after randomization.

• Progression-Free Survival (PFS)

  Up to 5 years after randomization.

Other Outcomes (2)

• Change in Gut Microbiome Diversity as Assessed by Metagenomic Sequencing

  Baseline and at the end of the dietary intervention period (week 4).

• Changes in Tumor-Infiltrating CD8⁺ T Cell Density and PD-L1 Expression as Assessed by Multiplex Immunohistochemistry

  At the time of radical surgery, approximately 24 weeks after initiation of neoadjuvant treatment.

Study Arms (2)

Serine/Glycine-Restricted Diet Plus Chemoradiotherapy and Immunotherapy

EXPERIMENTAL

Dietary Supplement: Serine/Glycine-Restricted Diet; Drug: CAPOX Chemotherapy; Drug: PD-1 Inhibitor; Radiation: Short-Course Radiotherapy

Chemoradiotherapy and Immunotherapy Without Dietary Restriction

ACTIVE COMPARATOR

Drug: CAPOX Chemotherapy; Drug: PD-1 Inhibitor; Radiation: Short-Course Radiotherapy

Interventions

CAPOX Chemotherapy DRUG

Oxaliplatin 130 mg/m² IV on day 1 of each 3-week cycle, plus capecitabine 1000 mg/m² orally twice daily on days 1-14 of each cycle, for a total of 6 cycles.

Chemoradiotherapy and Immunotherapy Without Dietary Restriction; Serine/Glycine-Restricted Diet Plus Chemoradiotherapy and Immunotherapy

PD-1 Inhibitor DRUG

PD-1 inhibitor administered intravenously every 3 weeks in combination with CAPOX chemotherapy as part of the neoadjuvant regimen.

Chemoradiotherapy and Immunotherapy Without Dietary Restriction; Serine/Glycine-Restricted Diet Plus Chemoradiotherapy and Immunotherapy

Serine/Glycine-Restricted Diet DIETARY_SUPPLEMENT

A specialized liquid nutritional powder free of serine and glycine, supplemented with a list of permitted low-serine/glycine foods. Patients receive 30 kcal/kg/day energy and 1.5 g/kg/day protein for 4 weeks during the neoadjuvant treatment period.

Serine/Glycine-Restricted Diet Plus Chemoradiotherapy and Immunotherapy

Short-Course Radiotherapy RADIATION

25 Gy delivered in 5 fractions (5 Gy/fraction) over 1 week, administered during the second week of Cycle 1 (C2, Week 1), concurrent with capecitabine.

Chemoradiotherapy and Immunotherapy Without Dietary Restriction; Serine/Glycine-Restricted Diet Plus Chemoradiotherapy and Immunotherapy

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent obtained prior to any study-related procedures.
• Male or female, aged 18-80 years.
• Histologically confirmed locally advanced rectal cancer staged as cT3, cT4, or node-positive by pelvic MRI.
• ECOG performance status score of 0 or 1.
• NRS-2002 score \< 3 (no significant nutritional risk).
• BMI ≥ 18.5 kg/m² (may be adjusted per actual conditions).
• Capable of oral intake or via feeding tube and able to tolerate enteral nutrition.
• Adequate organ function as defined by the following laboratory criteria:
• ANC ≥ 1.5×10⁹/L (without G-CSF support within 14 days); Platelet count ≥ 100×10⁹/L; Hemoglobin ≥ 9 g/dL (without transfusion or erythropoietin use within 7 days); Serum albumin ≥ 3.0 g/dL; Total bilirubin ≤ 1.5× ULN; AST and ALT ≤ 2.5× ULN; Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula) or serum creatinine ≤ 1.5× ULN; INR ≤ 1.5× ULN, PT and APTT ≤ 1.5× ULN; Urine protein \< 2+ (if ≥2+, 24-hour urine protein \< 2.0 g required for enrollment); Cardiac enzymes within normal range (isolated laboratory abnormalities without clinical significance permitted).
• Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to study treatment initiation and agree to use highly effective contraception from signing informed consent through at least 6 months after the last dose of study treatment.
• All patients (male or female) at risk of pregnancy must use contraceptive methods with a failure rate \< 1% per year throughout the treatment period and up to 120 days after the last dose of study treatment (or 180 days after the last dose of chemotherapy).

You may not qualify if:

• Stage I or Stage IV rectal cancer.
• Cognitive impairment or psychiatric disorders that prevent comprehension of the study content.
• Central nervous system or meningeal metastases.
• Clinically symptomatic moderate to severe ascites (requiring therapeutic paracentesis within 2 weeks before study treatment start; patients with small asymptomatic ascites may be enrolled).
• Uncontrolled or moderate to severe pleural effusion and pericardial effusion.
• Severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction; tracheoesophageal fistula, gastrointestinal perforation or fistula, or intra-abdominal abscess; gastrointestinal bleeding (CTCAE grade ≥ 3 within 6 months or grade ≥ 2 within 3 months before study treatment start, e.g., abnormal vaginal bleeding, hematemesis).
• Any other condition that may affect the study results or lead to forced discontinuation (e.g., alcohol abuse, drug abuse, serious concurrent diseases, severe laboratory abnormalities, family or social factors) as judged by the investigator.
• Known allergy to any active ingredient or excipient of the study drugs or nutritional powder.
• Poorly controlled diabetes mellitus.
• Severe cardiovascular disease, including cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction, or major vascular disease within 6 months prior to enrollment; uncontrolled symptomatic cardiac disease such as unstable angina, NYHA class II or higher heart failure, LVEF \< 50% on echocardiography, or severe arrhythmia not controlled by medication.
• Pregnancy or lactation.
• Any other condition that the investigator considers unsuitable for enrollment.

Sponsors & Collaborators

• Xuelei Ma MD: lead

Study Sites (1)

West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Interventions

Serine; Immune Checkpoint Inhibitors

Intervention Hierarchy (Ancestors)

Amino Acids, Neutral; Amino Acids; Amino Acids, Peptides, and Proteins; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Antineoplastic Agents, Immunological; Antineoplastic Agents; Therapeutic Uses

Central Study Contacts

Xuelei Ma, MD

CONTACT

13408410416; drmaxuelei@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Biotherapy Department, Deputy Director

Study Record Dates

• First Submitted: August 25, 2026
• First Posted: September 9, 2026
• Study Start: August 31, 2026
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): June 30, 2029
• Last Updated: September 9, 2026

Record last verified: 2026-09

Locations

CN (1)